Nlrp3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NLRP3 (NLR Family Pyrin Domain Containing 3) is a key component of the inflammasome complex. It is also known as NALP3 or cryopyrin, and plays a central role in innate immunity and inflammatory responses. NLRP3 is implicated in the pathogenesis of multiple neurodegenerative diseases through its role in neuroinflammation. [1]
| Property | Value | [2]
|---|---| [3]
| Protein Name | NLRP3 / NALP3 / Cryopyrin | [4]
| Gene Symbol | NLRP3 |
| UniProt ID | Q96P20 |
| Molecular Weight | 118 kDa |
| Structure | PYD, NACHT, LRR domains |
| Expression | Immune cells, neurons, astrocytes, microglia |
| Subcellular Localization | Cytoplasm |
NLRP3 is a pattern recognition receptor:
NLRP3 activation occurs through multiple pathways:
The NLRP3 inflammasome is one of the most well-characterized inflammasomes:
Key animal models for studying NLRP3:
| Drug/Compound | Mechanism | Status |
|---|---|---|
| MCC950 | Direct NLRP3 inhibitor | Phase II (COVID-19, MS) |
| Dapansutrile (OLT1177) | NLRP3 inhibitor | Phase I/II |
| Tranilast | NLRP3 inhibition | Approved (Japan, allergies) |
| Anti-IL-1β antibodies | Downstream blockade | Approved (IL-1Ra) |
| Caspase-1 inhibitors | Block inflammasome | Research |
The study of Nlrp3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Heneka MT, et al. NLRP3 is activated in Alzheimer's disease. Nat Neurosci. 2013. ↩︎
Gao J, et al. NLRP3 in Parkinson's disease. Mov Disord. 2020. ↩︎
Voet S, et al. NLRP3 inflammasome in microglia. Trends Neurosci. 2019. ↩︎
Coll RC, et al. NLRP3 inhibitors for inflammation. Nat Rev Drug Discov. 2019. ↩︎